Use of Yttrium-90 Radioembolization for Management of Colorectal Liver Metastases

详细信息    查看全文

• 作者：Ali A. Maawy ; Steven C. Rose ; Bryan Clary
• 关键词：SIR ; spheres ; Radioembolization ; Chemoembolization ; Yttrium ; 90 ; Microspheres ; Colorectal cancer ; Liver metastases
• 刊名：Current Colorectal Cancer Reports
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：12
• 期：5
• 页码：226-231
• 全文大小：270 KB
• 刊物主题：Oncology; Proctology; Colorectal Surgery;
• 出版者：Springer US
• ISSN：1556-3804
• 卷排序：12

文摘

Approximately 20 % of patients diagnosed with colorectal cancer present with metastatic disease at the time of diagnosis, predominantly to the liver. Surgical resection is the only real chance at a cure for a majority of these patients. A subset of patients present with unresectable disease with systemic and local therapy as the only available options. The advent of irinotecan- and oxaliplatin-based systemic therapy has increased median survival from about 5 months to greater than 20 months in metastatic disease. Addition of local therapy has the potential to further improve outcomes. With many avenues of regional therapy available, radioembolization with Yttrium-90 tagged microspheres offers a selective, targeted, and well-tolerated option. In this paper, we discuss the current evidence for radioembolization use as first-line adjunctive therapy and as salvage therapy. Based on current evidence, there appears to be an increase in liver-specific progression-free survival and an increase in overall survival when used as salvage therapy. Considerations for use in downstaging to resectable disease still need further investigation.